血清胸腺激酶1在转移性结直肠癌患者化疗前后检测的意义  

Significance of detecting serum thymidine kinase 1 in metastatic large intestine carcinoma before and after chemotherapy

作　　者：安宁[1] 张明[1] 兰海涛[1] 李宏敏[1] 

机构地区：[1]四川省医学科学院.四川省人民医院肿瘤科,四川成都610072

出　　处：《西部医学》2016年第9期1257-1260,共4页Medical Journal of West China

基　　金：四川省科技支撑计划项目(2015S2087)

摘　　要：目的探讨血清胸腺激酶1(S-TK1)在转移性结直肠癌患者化疗前后检测的意义。方法采用免疫印迹增强化学发光法检测45例转移性结直肠癌患者(结直肠癌组)和33例健康体检者(正常对照组)的S-TK1水平。结果转移性结直肠癌患者的S-TK1水平高于健康体检者(P<0.05);化疗后无疾病进展的转移性结直肠癌患者S-TK1水平较化疗前呈下降趋势(P<0.05),疾病进展的患者S-TK1水平较化疗前上升(P<0.05);转移性结直肠癌患者化疗前的S-TK1水平与其KPS评分有一定的相关性(P<0.05)。结论监测S-TK1水平对评估转移性结直肠癌患者的化疗疗效具有一定的临床应用价值。Objective To explore the significance of detecting serum thymidine kinase 1 （S-TK1） in metastatic large intestine carcinoma before and after chemotherapy. Methods Enhanced chemiluminescence assay was used to detect the S-TK1 levels in 45 patients with metastatic large intestine carcinoma and 33 normal controls. Results The S-TK1 level in the patients with metastatic large intestine carcinoma was significantly higher than that in the normal controls （P^0.05）. Compared with those before chemotherapy, the S-TK1 levels were significantly decreased in the metastatic large intestine carcinoma with disease under control after chemotherapy（P〈0.05）. S-TK1 levels were significantly increased in the metastatic large intestine carcinoma with PD after chemotherapy（P〈0.05）. S-TK1 level was statistically related with KPS scores of the metastatic large intestine carcinoma（P〈0.05）. Conclusion The detection of S-TK1 may have significance in the chemotherapy efficacy evaluation for metastati, c large intestine carcinoma.

关 键 词：血清胸腺激酶1 转移性结直肠癌 化疗 

分 类 号：R735.3[医药卫生—肿瘤]